June 2026 Penumbra received U.S. FDA clearance for its Thunderbolt™ Computer-Assisted Vacuum Thrombectomy (CAVT) platform for the treatment of acute ischemic stroke, expanding its portfolio of advanced mechanical thrombectomy solutions.
June 2026 Medtronic completed the acquisition of Scientia Vascular, strengthening its neurovascular portfolio with advanced microcatheters and access technologies used in minimally invasive stroke treatment procedures.
April 2026 Bayer announced that China's National Medical Products Administration accepted the marketing authorization application for asundexian for the prevention of recurrent ischemic stroke in patients following non-cardioembolic ischemic stroke or transient ischemic attack.
December 2025 Silver Creek Pharmaceuticals announced positive mid-stage clinical trial results for SCP-776 in acute ischemic stroke and continued advancing the therapy under the U.S. FDA Fast Track designation to address patients beyond the conventional treatment window.
November 2025 The Central Drugs Standard Control Organisation (CDSCO) approved India's first indigenously developed Supernova stent retriever for acute ischemic stroke treatment following successful multicenter clinical trials, expanding locally developed neurointerventional treatment options.
September 2025 Zylox-Tonbridge continued expanding its neurovascular R&D pipeline with late-stage development programs covering thrombectomy stents, aspiration systems, intracranial drug-eluting stents and ischemic stroke prevention devices to broaden its stroke intervention offerings.
July 2025 Penumbra expanded the global commercialization of its advanced thrombectomy portfolio for acute ischemic stroke through additional international market launches and regulatory clearances, strengthening access to minimally invasive stroke treatment technologies.